Aranesp® is also available in 150, 200, 300, and 500 mcg dose strengths. Aranesp® is available in single-dose vials and prefilled syringes, except the 10, 150, and 500 mcg dose strengths, which are available only as prefilled syringes.
The IV route of administration is recommended for adult patients on hemodialysis.
Aranesp® single-dose strengths can be
precisely titrate doses and individualize anemia
for patients with CKD on dialysis.1,*
With the 10 mcg dose strength, doses can be precisely
titrated within 5 mcg intervals.1,*
*Except 15 mcg dose.
DOWNLOAD Prescribing Information
Take a glance at the following doses to see which
single-dose strengths may be combined to individualize anemia management.
ARANESP® SINGLEJECT® PREFILLED SYRINGES
Following initiation of therapy and after each
adjustment, monitor Hb at least weekly
until the Hb
is stable and sufficient to minimize
the need for
When adjusting therapy, consider Hb rise, rate of decline,
responsiveness, and Hb variability.
Patients with CKD and an insufficient Hb
response to ESA therapy or a rate of Hb rise
of > 1 g/dL over 2 weeks may be at an even
greater risk for cardiovascular reactions
and mortality than other patients.
The dose conversions depicted above do not accurately estimate the once-monthly dose of Aranesp® in patients with CKD not on dialysis.
†For pediatric patients receiving a weekly epoetin alfa dose of < 1,500 units/week. The available data are insufficient to determine an Aranesp® conversion dose.
Remember to convert your patient's previous epoetin alfa per-administration dose to a per-week measurement. Here's an example how1:
Important Safety Information
If you decide to take Aranesp®, your healthcare provider should prescribe the smallest dose that is necessary to reduce your chance of needing RBC transfusions.
If your hemoglobin level stays too high or goes up too quickly, this may lead to serious health problems which may result in death. These serious health problems may happen if you take Aranesp®, even if you do not have an increase in your hemoglobin level.
Before taking Aranesp®, tell your doctor if you: have heart disease; have high blood pressure; have had a seizure or stroke; or if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed.
If you know you are allergic to latex, talk to your healthcare provider before using Aranesp® because the needle cover on the prefilled syringe contains latex.
These are not all the possible side effects of Aranesp®. Tell your healthcare provider about any side effects that bother you or do not go away.
You are encouraged to report negative side effects of prescription drugs to the US Food and Drug Administration (FDA). Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Aranesp® is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on dialysis and not on dialysis.
Aranesp® is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chemotherapy that will be used for at least two months after starting Aranesp®.
Aranesp® has not been proven to improve quality of life, fatigue, or well-being.
Aranesp® should not be used for the treatment of anemia: